EndoVx, Inc. is developing a novel medical device and system for non-invasively treating obesity.  The company’s approach is based on a successful study using conventional invasive surgery that showed effective long term weight loss.  EndoVx’s proprietary procedure is quick, bloodless, and done on an out-patient basis.  TASCF co-led the Series A round with Asset Management of Palo Alto.